Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/0002-9149(62)90375-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Compressed SENSE acceleration factor influence on magnetic resonance image quality in patients with endometrial cancer.
Phys Med
January 2025
Center for Radiology, University Clinical Center of Vojvodina, Hajduk Veljkova 1-9, 21000 Novi Sad, Serbia; Faculty of Sciences, University of Novi Sad, Trg Dositeja Obradovića 3, 21000 Novi Sad, Serbia. Electronic address:
Objectives: To investigate the impact of compressed sensing - sensitivity encoding (CS-SENSE) acceleration factor on the diagnostic performance of magnetic resonance imaging (MRI) within standard female pelvis protocol in patients with endometrial cancer.
Methods: T2-weighted turbo spin echo (TSE) sequence from standard female pelvic MRI protocol was chosen due to its long acquisition time and essential role in the evaluation of morphological characteristics of the female pelvic anatomical structures. Fully sampled reference scans and multiple prospectively 2x to 5x under-sampled CS-SENSE scans were acquired.
Prospective Multi-Site Validation of AI to Detect Tuberculosis and Chest X-Ray Abnormalities.
NEJM AI
October 2024
Google, Mountain View, CA, USA.
Background: Using artificial intelligence (AI) to interpret chest X-rays (CXRs) could support accessible triage tests for active pulmonary tuberculosis (TB) in resource-constrained settings.
Methods: The performance of two cloud-based CXR AI systems - one to detect TB and the other to detect CXR abnormalities - in a population with a high TB and human immunodeficiency virus (HIV) burden was evaluated. We recruited 1978 adults who had TB symptoms, were close contacts of known TB patients, or were newly diagnosed with HIV at three clinical sites.
Adjusting for switches to multiple treatments: Should switches be handled separately or combined?
Stat Methods Med Res
January 2025
Sheffield Centre for Health and Related Research, School of Medicine and Population Health, University of Sheffield, Sheffield, South Yorkshire, UK.
Treatment switching is common in randomised controlled trials (RCTs). Participants may switch onto a variety of different treatments, all of which may have different treatment effects. Adjustment analyses that target hypothetical estimands - estimating outcomes that would have been observed in the absence of treatment switching - have focused primarily on a single type of switch.
View Article and Find Full Text PDFCardiovascular safety of 5-fluorouracil and capecitabine in colorectal cancer patients: real-world evidence.
Cardiooncology
January 2025
Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Background: Fluoropyrimidines, including 5-fluorouracil and capecitabine, are the most common chemotherapeutic agents for colorectal carcinoma. Although previous studies have suggested varying degrees of cardiotoxicity with these drugs, there is a notable lack of large-scale investigations with appropriate control groups. This study aimed to evaluate cardiovascular outcome among colorectal carcinoma patients treated with fluoropyrimidines.
View Article and Find Full Text PDFAbsorptivity Is an Important Determinant in the Toxicity Difference between Aristolochic Acid I and Aristolochic Acid II.
J Agric Food Chem
January 2025
Department of Chemistry, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong.
Inadvertent exposure to aristolochic acids (AAs) is causing chronic renal disease worldwide, with aristolochic acid I (AA-I) identified as the primary toxic agent. This study employed chemical methods to investigate the mechanisms underlying the nephrotoxicity and carcinogenicity of AA-I. Aristolochic acid II (AA-II), which has a structure similar to that of AA-I, was investigated with the same methods for comparison.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!